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Background: Circulating-free DNA (cfDNA) is under investigation as a liquid
biopsy of cancer for early detection, monitoring disease progression and
therapeutic response. This systematic review of the primary cfDNA literature
aims to identify and evaluate factors that influence recovery of cfDNA, and to
outline evidence-based recommendations for standardization of methods.
Methods: A search of the Ovid and Cochrane databases was undertaken in May
2018 to obtain relevant literature on cfDNA isolation and quantification.
Retrieved titles and abstracts were reviewed by two authors. The factors
evaluated include choice of specimen type (plasma or serum); time-to-processing
of whole blood; blood specimen tube; centrifugation protocol (speed, time,
temperature and number of spins); and methods of cfDNA isolation and
quantification.
Findings: Of 4,172 articles identified through the database search, 52 proceeded to
full-text review and 37 met the criteria for inclusion. A quantitative analysis was not
possible, due to significant heterogeneity in methodological approaches between.e00699
vier Ltd. This is an open access article under the CC BY-NC-ND license
y-nc-nd/4.0/).
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approach was taken.
Interpretation: This is the first systematic review of methodological factors that
influence recovery and quantification of cfDNA, enabling recommendations to be
made that will support standardization of methodological approaches towards
development of blood-based cancer tests.
Keyword: Oncology
1. Introduction
In healthy individuals, circulating-free DNA (cfDNA) originates from apoptosis of
nucleated cells and is found at low levels in blood (Stroun et al., 2001) but can in-
crease following exercise (Fatouros et al., 2010). In malignancy, the tumor derived
fraction of total cfDNA, termed circulating tumor DNA (ctDNA), can derive from
tumor cells by a combination of apoptosis, necrosis and active secretion (Stroun
et al. 2001; Jahr et al., 2001), and from disseminated tumor cells in micrometastatic
deposits (Shaw et al., 2012; Gonzalez-Masia et al., 2013). Numerous studies have
demonstrated the potential of genetic and epigenetic alterations in ctDNA as
tumor-specific biomarkers to facilitate detection of resistance and relapse, and for
prediction of response to treatment (Alix-Panabieres and Pantel, 2016; Heitzer
et al., 2015; Diaz et al., 2016).
The number of cfDNA-related publications has risen rapidly since the mid-1990s
(Fig. 1 and Supplemental Table S1). However, the community is yet to agree on a
consensus for the isolation and analysis of cfDNA, thus limiting comparison be-
tween studies. This issue was highlighted at the consensus meeting on cfDNA,
hosted by the Experimental Cancer Medicine Centre (ECMC) Network and the Na-
tional Cancer Research Institute Biomarkers and Imaging Clinical Studies Group
(UK). It was agreed that a systematic review would be of use to the cfDNA commu-
nity to identify and evaluate the methodological factors that influence quality and
yield of cfDNA (ECMC, 2014). In support of this, there is wide variation in the
methods used to isolate plasma from whole blood and to extract cfDNA (Fig. 2).
We randomly sampled 50 primary research articles published in 2015 relating to
cfDNA in cancer and found deficiencies in reporting of methodology. Sixteen arti-
cles provided no information regarding plasma/serum isolation and a further 19
mentioned centrifugation but did not state the speed or number of centrifugation
steps. Lastly, 18 articles provided no information on cfDNA quantification prior
to downstream analysis (Supplemental Table S2). Therefore, we carried out a sys-
tematic review of the cancer cfDNA literature with the aim of providing a series
of methodological recommendations to promote optimal and reproducible process-
ing and analysis of cfDNA. After scoping the literature, we determined there wason.2018.e00699
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 1. Number of publications by year relating to cfDNA in cancer between 1995 and 2017. The search
was conducted in PubMed using search terms combined with Boolean operators, as follows: (ccfDNA
OR cfDNA OR cfNA OR ctDNA OR cell-free DNA OR cell free DNA OR cell-free serum DNA OR
circulating DNA OR circulating free DNA OR circulating-free DNA OR circulating nucleic acids OR
circulating tumor DNA OR free DNA OR free tumor DNA OR plasma DNA OR plasma tumor DNA
OR ptDNA OR serum DNA OR serum cell-free) AND (cancer OR neoplas* OR tumor). Publications
relating to cell-free DNA in non-blood analytes (e.g. urine and ascites) and cell culture media were
not included. A yearly breakdown of publication types is presented in Supplemental Table S1.
Fig. 2. Methodological variables in processing and analysis of cfDNA.
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(plasma or serum); (2) time-to-processing of whole blood and choice of blood spec-
imen tube; (3) centrifugation speed, number of spins and centrifugation time of
whole blood; (4) cfDNA isolation method; and (5) cfDNA quantification method.
The search was updated in May 2018 to ensure inclusion of recent publications.2. Materials and methods
This systematic review was guided by the criteria of the Preferred Reporting Items
for Systematic Reviews and Meta Analyses (PRISMA) (Supplemental Table S3)
(Moher et al., 2010).on.2018.e00699
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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An initial scoping search in Ovid (Embase and Medline) was carried out to assess for
appropriateness, and relevant publications were identified from which keywords
were obtained. A comprehensive publication search was conducted in the PubMed,
Ovid (Embase and Medline) and Cochrane library databases prior to July 28, 2017
(updated to May 5, 2018) without limits for language, publication type or publica-
tion date. Keywords were chosen to reflect the concepts of ‘circulating-free
DNA’, ‘cancer’ and ‘methodology’, with provision for alternative spellings, syno-
nyms and abbreviations for circulating-free DNA. Keywords were combined using
Boolean operators and translated into database-specific syntax, and were searched in
title and abstract only. The final search strategy was as follows: ((ccfDNA OR
cfDNA OR cfNA OR ctDNA OR cell-free DNA OR cell free DNA OR cell-free
serum DNA OR circulating DNA OR circulating free DNA OR circulating-free
DNA OR circulating nucleic acids OR circulating tumo?r DNA OR free DNA
OR free tumo?r DNA OR plasma DNA OR plasma tumo?r DNA OR ptDNA OR
serum DNA OR serum cell-free) AND (cancer OR neoplas* OR tumo?r) AND (pro-
cess* OR isolat* OR centrifug* OR spin* OR extract* OR quanti* OR sensitiv* OR
specific* OR measur*)). Question marks and asterisks represent optional wildcards
and truncations, respectively. As an example, the search strategy for Ovid (Embase
and Medline) is shown in Table 1. All returned studies were reviewed by title and
abstract by two authors. Additional studies were identified through a manual search
of bibliographies in included studies and relevant narrative reviews. Authors of the
following publications were contacted by email for further information: Chiminqgi
et al., 2007; Holdenrieder et al., 2005; Morgan et al., 2012; Swinkels et al., 2003; and
Taback et al., 2004. Conference abstracts were excluded due to insufficient detail for
valid assessment.2.2. Selection criteria
Studies investigating the effect of methodological factors on quality and/or yield of
cfDNA proceeded to full-text review. The criteria for inclusion were as follows: (1)
provided a direct comparison between two or more protocols in processing/analysis
of circulating-free DNA; (2) n  5 for any comparative study; and (3) absolute
values stated (or available through author contact) for quantitative data. The criteria
for exclusion were as follows: (1) n< 5 for any comparative study; (2) only pregnant
female subjects; (3) qualitative data or insufficient data available (despite further in-
formation provided by author contact) for valid analysis; (4) specific research ques-
tions not addressed; (5) unsuitable publication types, such as commentaries,
editorials and review articles without data; and (6) duplicate publication. All
included studies (n ¼ 36) and 320 randomly selected publications, approximatelyon.2018.e00699
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 1. Literature search strategy for Ovid (Embase and Medline).
ID Search
1 (ccfDNA OR cfDNA OR cfNA OR ctDNA)
[kw,ti,ab]
2 (cell-free DNA OR cell-free serum OR cell
free DNA OR cell free serum) [kw,ti,ab]
3 (circulating DNA OR circulating free DNA
OR circulating-free DNA OR circulating
nucleic acids OR circulating tumo?r DNA)
[kw,ti,ab]
4 (free DNA OR free tumo?r DNA) [kw,ti,ab]
5 (plasma DNA OR plasma tumo?r DNA OR
ptDNA) [kw,ti,ab]
6 (serum DNA OR serum cell-free OR serum
cell free) [kw,ti,ab]
7 1 OR 2 OR 3 OR 4 OR 5 OR 6
8 (neoplasms) [sh,ti,ab]
9 (centrif* OR process* OR spin*) [kw,ti,ab]
10 (extract* OR isolate*) [kw,ti,ab]
11 (quanti* OR measure*) [kw,ti,ab]
12 (sensitiv* OR specific*) [kw,ti,ab]
13 9 AND 10 AND 11 AND 12
14 7 AND 8 AND 13
ab, abstract word; kw, keyword; ti, title word; sh, subject heading (i.e. MeSH); ?, wildcard; *, truncation.
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(LJM). Included studies were also reviewed to check for additional references not
generated by the data mining process.2.3. Data extraction and analysis
The following data were independently extracted into an electronic table by two re-
viewers: first author, year of publication, number of subjects in each group, health
status of subjects, gender of subjects (if stated), cfDNA isolation method, cfDNA
quantification method, technical details of protocol and mean (with standard devia-
tion and/or range if stated) of any measurements. Where data were presented graph-
ically but not specified numerically, individual data points were estimated by two
observers by interpolating graphs. A quantitative analysis was not deemed possible,
due to significant heterogeneity in methodological approaches between studies.
Therefore, included data was tabulated and a textual qualitative synthesis approach
was taken.on.2018.e00699
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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3.1. Literature search and study characteristics
The literature search and inclusion/exclusion process is shown in Fig. 3. A total of
5,888 articles were identified through database searching and 4,172 articles remained
after duplicated articles were removed. All articles were screened with title and ab-
stract against the inclusion and exclusion criteria, and 48 articles proceeded to full-
text review. The review process identified a further 4 articles. Of the 52 articles that
were reviewed by full-text, 15 were excluded for one or more of the following rea-
sons: (i) insufficient cohort size (n < 5) for a comparative study (n ¼ 5); (ii) only
pregnant female subjects (n ¼ 1); (iii) insufficient quantitative data (n ¼ 4); (iv) spe-
cific research questions not addressed (n ¼ 4); and (v) duplicated data from another
publication (n¼ 1). Studies with only pregnant female subjects were not included, as
the biological characteristics of fetal cfDNA may not be comparable to those for
tumor-derived cfDNA. Due to the broad search strategy adopted, a large number
of publications were retrieved.
A total of 37 articles met all inclusion criteria and no exclusion criteria, and were
included in the narrative synthesis (Table 2). Studies were published betweenIN
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Fig. 3. PRISMA flow diagram of literature search and inclusion/exclusion process.
on.2018.e00699
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 2. Summary characteristics of included studies.
Author
(et al)
Year Subjects cfDNA
Isolation method Quantification
method
Bartak 2018 Cancer; benign;
healthy
Multiple commercial kits FL
Board 2008 Cancer; healthy QIAamp Virus Spin Kit qPCR
Chan 2005 Cancer QIAamp DBM Kit qPCR
Chiminqgi 2007 Cancer; healthy QIAamp Blood Kit qPCR, FL
Denis 2015 Cancer iPrep PureLink Virus Kit qPCR
Devonshire 2014 Healthy Multiple commercial kits dPCR, qPCR
Diaz 2016 Healthy QIAamp DNA Blood Mini Kit qPCR
Fleischhacker 2011 Cancer; benign
disease
Multiple commercial kits qPCR
Fong 2009 Cancer Multiple commercial kits qPCR, FL
Garcia 2017 Cancer QIAamp CNA Kit qPCR, FL
Jung 2003 Healthy NucleoSpin Blood Kit qPCR
Kadam 2012 Cancer QIAamp DBM Kit qPCR
Kang 2016 Cancer QIAamp CNA Kit dPCR
Kloten 2017 Cancer; healthy Multiple commercial kits dPCR
Lam 2004 Healthy QIAamp DBM Kit qPCR
Lee 2001 Healthy HIV Monitor Assay qPCR
Lui (a) 2002 Healthy QIAamp Blood Kit qPCR
Lui (b) 2002 Healthy QIAamp Blood Kit qPCR
Mauger 2015 Cancer Multiple commercial kits qPCR, FL
Markus 2018 Healthy QIAamp CNA Kit dPCR
Mazurek 2013 Cancer Multiple commercial kits qPCR
Morgan 2012 Cancer QIAamp CNA Kit qPCR
Norton 2013 Healthy QIAamp CNA Kit dPCR
Page 2013 Healthy Multiple commercial kits qPCR
Park 2012 Cancer QIAamp UltraSens Virus Kit qPCR
Parpart-Li 2017 Cancer QIAamp CNA Kit dPCR, FL
Ramachandran 2013 Suspected cancer QIAamp UltraSens Virus Kit qPCR, FL, SP
Rothwell 2015 Healthy QIAamp CNA Kit qPCR
Sherwood 2016 Cancer QIAamp CNA Kit qPCR
Swinkels 2003 Healthy QIAamp Blood Kit qPCR
Szpechcinski 2008 Cancer QIAamp DBM Kit qPCR, FL
Taback 2004 Cancer QIAamp extraction Kit FL
Thijssen 2002 Cancer; healthy QIAquick PCR Purification Kit qPCR, FL
Toro 2015 Cancer QIAamp CNA Kit dPCR
(continued on next page)
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Table 2. (Continued )
Author
(et al)
Year Subjects cfDNA
Isolation method Quantification
method
Umetani 2006 Cancer None qPCR
van Dessel 2017 Cancer QIAamp CNA Kit FL
Van Ginkel 2017 Cancer; healthy Multiple commercial kits FL
CNA, Circulating Nucleic Acid; DBM, DNA Blood Mini; dPCR, digital polymerase chain reaction; FL,
fluorometry; qPCR, quantitative real-time polymerase chain reaction; SP, spectrophotometry.
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healthy subjects only, 17 recruited patients with cancer only, and 6 recruited both.
One study recruited patients with suspected cancer and one study combined patients
with different health statuses into a single cohort for analysis. Cohort size ranged be-
tween 5 and 156 subjects.
Ten studies investigated cfDNA levels in matched plasma and serum, 19 studies
investigated the effect of time delay post-venepuncture on cfDNA levels in plasma
using different collection tubes, 6 studies investigated the effect of centrifugation
speed and time on cfDNA levels in plasma, 10 studies compared efficiency of
cfDNA extraction between different commercially available kits, and 8 studies
compared methods of cfDNA quantification. Several different methods were used
to quantify cfDNA. Polymerase chain reaction (PCR) was the most commonly
used method, with 27 studies using quantitative real-time PCR (qPCR) and 7 studies
using digital PCR (dPCR). Ten studies used a fluorescent DNA-binding dye (fluor-
ometry), and one study used ultraviolet spectrophotometry. Eight studies utilized
two or more quantification methods. The cfDNA concentration was expressed as
either ng/mL or haploid genome equivalents (copies)/mL. Two studies reported total
amounts per plasma/serum sample, one study used cell equivalents/mL and one
study used copies/mL. To permit a direct comparison between studies in this review,
haploid genome equivalents (copies) were multiplied by 3.3  103 to give ng.
Lastly two qPCR-based studies reported cycle threshold (CT) values only which
could not be interpolated to give the cfDNA concentration.3.2. Choice of specimen type (plasma or serum)
Ten studies investigated yield of cfDNA from matched plasma and serum samples.
Total cfDNA levels were between 1.63 and 11.09-fold higher in serum than in
plasma of healthy controls and patients with cancer (Table 3). Two studies that
met the inclusion criteria also assessed integrity of cfDNA in plasma and serum
(Chan et al., 2005; Holdenrieder et al., 2008). Using a ratio of 201 bp/105 bp ampli-
cons, cfDNA isolated from serum was found to have significantly higher integrityon.2018.e00699
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 3. Extracted data from studies addressing blood specimen type. Where data were expressed as
copies or haploid genome equivalents per mL, values were multiplied by 0.0033 ng to reach ng/mL. y,
median values. *, values were estimated by reading off a graph, #, data for two different extraction
methods were combined in the original paper.
Author
(et al)
Subjects (n) Isolation method Quantification method Mean serum
(ng/mL)
Mean
plasma
(ng/mL)
Ratio serum:
plasma
Board Healthy (10) QIAamp Virus Spin Kit qPCR (AAT, 77 bp) 24.65 5.07 4.86
Chan Healthy (27) QIAamp DBM Kit qPCR (LEP, 105 bp) 3.2* 2.0* 1.63
Jung Healthy (10) NucleoSpin Blood Kit qPCR (HBB, 110 bp) 8.3* 4.0* 2.08
Kloten Healthy (8) Maxwell RSC qPCR (KRAS) 2300 450 4.18
Cancer (50) ccfDNA Plasma kit
and QIAamp CNA Kit
Lee Healthy (6) HIV Monitor Assay qPCR (HLA-DQA1, 242 bp) 33* 9.9* 3.33
Park Cancer (130) QIAamp UltraSens
Virus Kit
qPCR (ALU repeat, 81 bp) 755.9 68.7 11.00
Taback Cancer (10) QIAamp Extraction Kit PicoGreen 1059y 259y 4.09
Thijssen Healthy (28) QIAquick PCR
Purification Kit
PicoGreen 12.9 4.8 2.69
Cancer (26) 47.6 10.6 4.49
Umetani Cancer (24) None qPCR (ALU repeat, 115 bp) 970 180 5.39
van Ginkel Healthy (25) QIAamp CNA Kit
and MagNA
Pure LC DNA
Isolation Kit
dPCR (BRAF, 91 bp)# 673.2 60.72 11.09
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tween specimens was greater with a 356 bp/105 bp ratio, at 26% vs 12% for serum
and plasma, respectively, thus supporting the presence of high molecular weight
DNA from hematopoietic cells in serum (Chan et al., 2005). Although KRAS allelic
frequencies were much lower than expected in serum samples compared to plasma
(Kloten et al., 2017), serum was still a useful source for recovery of ctDNA, as
plasma and serum were comparable in terms of sensitivity (31% and 25%, respec-
tively) and specificity (97% and 100%, respectively) (Morgan et al., 2012).3.3. Time-to-centrifugation of blood and blood specimen tube
The effect of time delay between venepuncture and centrifugation of blood on
cfDNA levels has been reported by several groups, with the general observation
that cfDNA levels increase over time prior to centrifugation of EDTA-stabilized
blood (Page et al., 2011). To overcome the need for immediate blood processing,
specialized blood collection tubes are available that contain a preservative agent
to prevent lysis of peripheral leukocytes and permit storage of whole blood at
room temperature for several days prior to centrifugation; these include the Cell-
Free DNA BCT (Streck) and PAXgene Blood DNA Tube (Qiagen). Nineteenon.2018.e00699
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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over time points ranging up to 14 days (Table 4). Eight studies investigated EDTA
tubes only, 2 studies investigated a single specialized tube, 8 studies compared
EDTA tubes with one or more specialized tubes (Cell-Free DNA BCT, CellSave
and PAXgene Blood DNA Tube), and one study compared two specialized tubes.
Table 4 summarizes the included studies and shows the stability of blood, which was
defined as the longest time post-venepuncture at which cfDNA levels remained sta-
ble relative to at baseline levels (i.e. immediate centrifugation of blood), as deter-
mined by the Student’s t-test on paired plasma samples.
Of the studies that investigated EDTA tubes, 10 studies included a baseline of 0 hours
(i.e. immediate centrifugation) and the minimum stability was 6 hours in these
studies. Two studies did not assess stability beyond 6 hours and in both studies
cfDNA was stable for this time. Concerning longer times to processing, 6 of 9
studies that included a 24 hour time point reported stability for this duration.
Ten studies used the Cell-Free DNA BCT, 2 studies used the CellSave tube (Cell-
Search) and 1 study used the PAXgene Blood DNA Tube. The Cell-Free DNA
BCT is reported to stabilize cfDNA for up to 14 days post-venepuncture. In 8 of
the 10 studies that used the Cell-Free DNA BCT, cfDNA was stable up to the
last time point (24 hourse10 days). One study showed a significant increase in
cfDNA levels after 72 hours (relative to 2 hours), and another study demonstrated
stability for up to 7 days but not 14 days. Lastly, one study measured ctDNA, where
there was a trend at day 3 towards a decrease in ctDNA levels in both BCT and
EDTA tubes (Parpart-Li et al., 2017).
In the 2 studies that used CellSave tubes, cfDNA was stable up to the last time point
(48 hours and 4 days). One study used the PAXgene Blood DNA Tube and as-
sessed cfDNA levels after 24 hours and 7 days. Here cfDNA levels were signifi-
cantly elevated after 7 days.3.4. Centrifugation protocol: speed, time, temperature and
number of spins
Six studies investigated the effect of centrifugation speed (range, 400ge16,000g) on
cfDNA recovery from EDTA plasma, and 5 of these studies also investigated the
addition of a second centrifugation step (Table 5). A second centrifugation step
had no significant effect on DNA yield apart from in one study where this was asso-
ciated with a significant reduction, suggesting that differences may be due to removal
of plasma without disturbing the buffy layer after the first spin. Lui et al. (2002)
observed no significant differences in DNA yield with single centrifugations of 10
minutes at 400g, 800g, 1,500g, 3,000g and 16,000g. Similarly, Page et al. (2013)
reported no significant difference in DNA yields at 1,000g, 2,000g and 10,000gon.2018.e00699
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 4. Extracted data from studies addressing time-to-processing of blood. Stability is defined as the longest time point post-venepuncture in which
cfDNA levels were not significantly elevated relative to at baseline (i.e. immediate processing of blood). All blood was stored at room temperature prior
to processing unless indicated with a cross (y), indicating separate experiments were conducted on samples stored at both room temperature and 4 C. d,
days.
Author (et al) Subjects (n) Isolation method Quantification method Tube type Time points
(hours)
Stability
(hours)
Board Healthy (10) QIAamp Virus Spin Kit qPCR (AAT, 77 bp) EDTA 0, 2, 4, 8, 24 24
Chan Healthy (27) QIAamp DNA Blood Mini Kit qPCR (LEP, 105 bp) EDTAy 0, 6, 24 6y
Garcia Cancer (7) QIAamp Circulating Nucleic Acid Kit qPCR (hTERT, 62 bp) EDTAy 4, 24 24
Jung Healthy (10) NucleoSpin Blood Kit qPCR (HBB, 110 bp) EDTAy 0, 2, 4, 8 8y
Lam Healthy (10) QIAamp Blood Kit qPCR (HBB, 102 bp) EDTA 0, 2, 6, 24 6
Lui Healthy (8) QIAamp Blood Kit qPCR (HBB, 102 bp) EDTA 0, 3, 6 6
Page Healthy (5) QIAamp DNA Blood Mini Kit qPCR (GAPDH, 96 bp) EDTA 2, 6 6
Denis BRAFV600E-positive
Melanoma (9)
iPrep PureLink Virus Kit therascreen BRAF RGQ
PCR Kit
EDTA 2, 4d, 7d, 10d 2
Cell-Free DNA BCT 2, 4d, 7d, 10d 10d
Diaz Healthy (60) QIAamp DNA Blood Mini Kit qPCR (LINE-1, 96 bp) Cell-Free DNA BCT 2, 3d, 5d 5d
Kadam Metastatic cancer (10) QIAamp DNA Blood Mini Kit qPCR (ACTB, 182 bp) EDTA 0, 24 24
NucleoSpin Plasma XS Kit Cell-Free DNA BCT 0, 24 24
EDTA 0, 24 0
Cell-Free DNA BCT 0, 24 0
Kang Metastatic cancer (6) QIAamp Circulating Nucleic Acid Kit dPCR (PIK3CA and TP53) EDTAy 0, 6, 48 6y
Cell-Free DNA BCTy 0, 6, 48 48y
CellSave 0, 6, 48 48
(continued on next page)
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Table 4. (Continued )
Author (et al) Subjects (n) Isolation method Quantification method Tube type Time points
(hours)
Stability
(hours)
Markus Healthy (23) QIAamp Circulating Nucleic Acid Kit dPCR (9 single-copy loci) Cell-Free DNA BCTy 24, 48 48
Norton Healthy (12) QIAamp Circulating Nucleic Acid Kit qPCR (HBB, 136 bp) EDTA 0, 24, 48, 72, 7d, 14d 24
Cell-Free DNA BCT 0, 24, 48, 72, 7d, 14d 7d
Parpart-Li Cancer (9) QIAamp Circulating Nucleic Acid Kit dPCR (proprietary BRAF,
EGFR and KRAS assays)
EDTA 0, 24, 72, 5d, 7d 0
Cell-Free DNA BCT 0, 24, 72, 5d, 7d 7d
Rothwell Healthy (20) QIAamp Circulating Nucleic Acid Kit qPCR (RPPH1, 87 bp) EDTA 4, 4d 4
CellSave 4, 4d 4d
Sherwood Lung cancer (20) QIAamp Circulating Nucleic Acid Kit qPCR (RPPH1, 87 bp) EDTA 2, 72 2
Cell-Free DNA BCT 2, 72 2
Toro Metastatic breast
cancer (9)
QIAamp Circulating Nucleic Acid Kit dPCR (proprietary
PIK3CA assays)
Cell-Free DNA BCT 24, 7d 7d
PAXgene Blood DNA Tube 24, 7d 24
van Dessel Cancer (16) QIAamp Circulating Nucleic Acid Kit qPCR (b actin, 136 bp) EDTA 1, 24, 96 24
Cell-Free DNA BCT 1, 24, 96 96
CellSave 1, 24, 96 96
van Ginkel Healthy (6) Quick-cfDNA serum & plasma Kit (Zymo
Research)
dPCR (RRP30, 98 bp) EDTA 0, 3, 6, 24 24
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Table 5. Extracted data from studies addressing centrifugation speed and number of spins. 2 indicates two centrifugations at the given speed, with
removal of plasma from the cellular fraction or debris before the second centrifugation. *second centrifugation was conducted following freezing, then
post-thawing of sample.
Author (et al) Subjects (n) Isolation method PCR assay First speed (g) Second speed (g) Effect on cfDNA yield
Lui (a) Healthy (14) QIAamp Blood Kit HBB, 102 bp 3,000 16,000 No significance
(3,000) 2 16,000
(3,000) 2 (16,000) 2
Page Healthy (5) QIAamp DNA Blood Mini Kit GAPDH, 96 bp 1,000 1,000 No significance
1,000 2,000
1,000 10,000
Sherwood Healthy (5) QIAamp Circulating Nucleic Acid Kit RPPH1, 87 bp 2,000 None No significance
2,000 2,000
Lui (b) Healthy (10) QIAamp Blood Kit HBB, 102 bp 400 None No significance
800 None
1,500 None
3,000 None
16,000 None
Swinkels Healthy (10) QIAamp Blood Kit HBB, 81 bp 800 None Significantly lower yield after second spin (p
¼ 0.01)800 16,000
van Ginkel Healthy (6) Quick-cfDNA serum & plasma Kit (Zymo
Research)
dPCR (RRP30, 98 bp) 800 None
800 11,000 No significance
800 11,000*
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Article Nowe00699for 10 minutes. However, Swinkels et al. (2003) reported that after an initial centri-
fugation at 800g for 10 minutes, a second centrifugation step at 16,000g for 10 mi-
nutes significantly reduced DNA yield. Interestingly, Sherwood et al. (2016) found
that double centrifugation at 2,000g for 10 mins did not decrease DNA yield relative
to single centrifugation of blood processed 2 hours post-collection, but the second
step significantly reduced DNA yield in blood processed 72 hours post-collection.
This suggests that contaminating nuclear DNA was present at 72 hours due to lysis
of white blood cells that was not efficiently pelleted by a single centrifugation step.
Lastly, van Ginkel et al. (2017) also incorporated a freeze thaw step between the first
and second centrifugation steps, but this did not affect recovery.
Four studies (Chan et al., 2005; Garcia et al., 2017; Jung et al., 2003; Kang et al., 2016)
investigated the effects of storage temperature of unprocessed blood in EDTA tubes
and reported no significant influence of temperature on resulting cfDNA levels.3.5. Methods of cfDNA isolation and quantification
Methods of cfDNA isolation reported varied from in-house protocols to the use of
commercially available kits. Of these, the QIAamp Circulating Nucleic Acid Kit
(Qiagen) was most widely used (Tables 6 and 7). Page et al. (2013) showed that
this kit led to the highest yield of total cfDNA. qPCR was the most widely used
method for cfDNA quantification, while fluorometry (e.g. PicoGreen and Qubit)
was also widely used as a cost-effective, rapid and simple method. Ramachandran
et al. (2013) also compared qPCR with fluorometry and UV spectrophotometry
(Table 7). Total cfDNA levels were significantly correlated in all studies that
compared qPCR and fluorometry (PicoGreen or Qubit) (r  0.72; P < 0.05),
except for in one study (Mauger et al., 2015). Ramachandran et al. (2013) reported
that cfDNA levels quantified by qPCR were not significantly correlated with UV
spectrophotometry (r ¼ 0.23) (not included in Table 7) and van Ginkel showed pos-
itive correlation between dPCR and fluorometry by Qubit (r¼ 0.98; P< 0.0001) but
not UV spectrophotometry (Nanodrop).4. Discussion
We systematically reviewed the cfDNA literature in order to investigate the influ-
ence of preanalytical and analytical factors on quality and/or yield of cfDNA for sub-
sequent molecular analysis of ctDNA. Of 4,176 articles retrieved by database and
bibliography searching, 37 articles were identified that met all inclusion criteria
and were included in the review. Given the heterogeneity observed across the
included studies, we took a narrative approach to data synthesis and tabulated the
relevant data to examine the following factors: (1) choice of specimen type (plasma
or serum); (2) time-to-processing of whole blood and choice of blood specimen tube;on.2018.e00699
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 6. Summary of studies comparing cfDNA isolation methods. *pooled plasma samples. FL,
fluorometry.
Author (et al) Subjects (n) Isolation methods Quantification method
Board Healthy (5) QIAamp Mini Blood Kit qPCR (AAT, 77 bp)
GENFIND Blood & Serum Genomic DNA
Isolation Kit
QIAamp Virus Spin Kit
ChargeSwitch gDNA Serum Kit
Devonshire Healthy (5)* QIAamp Circulating Nucleic Acid Kit qPCR (TERT, 79 bp;
ALUJ, various length)NucleoSpin Plasma XS Kit
FitAmp Plasma/Serum DNA Isolation Kit
QIAamp DNA Blood Mini Kit
Fleischhacker Cancer (36),
benign disease (8)
QIAamp DNA Blood Mini Kit qPCR (ERV, 135 bp;
GAPDH, 92 bp; HBB, 101 bp)NucleoSpin Plasma F Kit
MagaPure LC DNA Isolation Kit
Fong Healthy (5)* QIAamp DNA Blood Midi Kit FL, qPCR (CHD1,
68 bp, ACTB, 115 bp)Puregene DNA Purification System Cell and
Tissue Kit
ChargeSwitch gDNA Serum Kit
ZR Serum DNA Kit
Kloten Healthy (8)
Cancer (50)
Maxwell RSC qPCR (KRAS)
ccfDNA Plasma kKt and QIAamp
Circulating Free Nucleic Acid Kit
Mauger Cancer (4), healthy (1) QIAamp Circulating Nucleic Acid Kit qPCR (KPN, 55 bp)
Norgen Plasma/Serum Cell-Free Circulating
DNA
Norgen Plasma/Serum Circulating DNA
Purification Mini Kit
NucleoSpin Plasma XS Kit
Chemagic NA Extraction Kit
Mazurek Cancer (10) QIAamp DNA Blood Mini Kit qPCR (TERT, 98 bp)
QIAamp Circulating Nucleic Acid Kit
Sherlock AX kit
Page Healthy (1) QIAamp DNA Blood Mini Kit
QIAamp Circulating Nucleic Acid Kit
NucleoSpin Plasma XS Kit
FitAmp Plasma/Serum DNA Isolation Kit
qPCR (GAPDH, 96 bp,
ACTBL2 67 bp and HPRT1 64 bp)
Sorber Cancer (10) QIAamp Circulating Nucleic Acid Kit FL
PME free-circulating DNA Extraction Kit
Maxwell RSC ccfDNA Plasma Kit
EpiQuikTM Circulating Cell-Free DNA
Isolation Kit
NEXTprep-MagTM cfDNA Isolation Kit v1
NEXTprep-MagTM cfDNA Isolation Kit v2
van Ginkel Healthy (4) QIAamp Circulating Nucleic Acid Kit dPCR (BRAF, 91 bp)
PME free-circulating DNA Extraction Kit
Quick-cfDNA Serum & Plasma Kit
15 https://doi.org/10.1016/j.heliy
2405-8440/ 2018 Published
(http://creativecommons.org/li
Article Nowe00699(3) centrifugation speed, time, temperature and number of spins of whole blood; (4)
cfDNA isolation method; and (5) cfDNA quantification method. Table 8 summarizes
the evidence-based methodological recommendations to promote best practice in
processing and analysis of cfDNA.on.2018.e00699
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 7. Extracted data from studies comparing cfDNA quantitation method. *quantitative data not available.
Author (et al) Subjects (n) Isolation method Quantification methods Results
Chiminqgi Healthy (58)
Colorectal (87) and
prostate (93) cancer
QIAamp Blood Kit PicoGreen dsDNA Kit (qPCR HBB, 102
bp; PPIA, 105 bp)
PicoGreen correlated with qPCR targeting
HBB (r ¼ 0.915) and PPIA (r ¼ 0.81).
Devonshire Healthy (17) QIAamp Circulating Nucleic Acid Kit qPCR and dPCR (ERV3, 135 bp; TERT, 79
bp, RPPH1, 64 bp)
Good agreement between the qPCR and
droplet dPCR measurements of copy
number*
Garcia Cancer (7) QIAamp Circulating Nucleic Acid Kit qPCR (hTERT, 62 bp), FL Good agreement between qPCR and Qubit
FL (r2 ¼ 0.85; P < 0.00)
Mauger Healthy (2)
Colon (2), pancreatic (2),
lung (2) and breast (2) cancers
Norgen Plasma/Serum Circulating DNA
Purification Mini Kit
QIAamp Circulating Nucleic Acid Kit
Qubit dsDNA HS assay; qPCR (DHFRP2,
102 bp; KPN, 102 bp)
Qubit did not correlate with qPCR assays
targeting KPN (r ¼ 0.04; P ¼ 0.91) and
DHFRP2 (r ¼ 0.14; P ¼ 0.70).
Qubit correlated with qPCR assays targeting
KPN (r ¼ 0.75; P ¼ 0.01) and DHFRP2 (r ¼
0.72; P ¼ 0.02).
Ramachandran Healthy (156) and
prostate cancer (85)
QIAamp UltraSens Virus Kit PicoGreen dsDNA Kit; qPCR (GSTP1, 95
bp); UV spectrophotometry
PicoGreen correlated with qPCR (r ¼
0.8552; P < 0.0001).
UV absorbance weakly correlated with
PicoGreen (r ¼ 0.2376) and qPCR (r ¼
0.2274).
Szpechcinski Lung cancer (10) QIAamp DNA Blood Midi Kit PicoGreen dsDNA Kit; qPCR (ACTB, 99
bp) by SYBR Green and TaqMan
PicoGreen correlated with SYBR Green
qPCR (r ¼ 0.87; P < 0.0001) and TaqMan
qPCR (r ¼ 0.94; P < 0.0001). SYBR Green
and TaqMan qPCR were correlated (r ¼
0.96; P < 0.0001).
Thijssen Colorectal cancer (26) Isopropanol precipitation followed by
QIAquick PCR Purification Kit
PicoGreen; dsDNA Kit qPCR (ALB, 81 bp) PicoGreen correlated with qPCR (P < 0.05).
van Ginkel Healthy (33 e Nanodrop)
and Healthy (78 e Qubit)
Multiple commercial kits dPCR vs Nanodrop and Qubit respectively dPCR positively correlated with Qubit (r2 ¼
0.98; P < 0.0001). Nanodrop did not
correlate with dPCR (r2 ¼ 0.04; P ¼ 0.81).
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Table 8. Evidence-based methodological recommendations for processing and analysis of cfDNA.
*insufficient data available to comment on other methods (e.g. digital PCR).
Methodological factor Recommendation Justification
Blood specimen type Plasma for analytical techniques that are
sensitive to a wild-type DNA background;
plasma or serum for all other techniques.
cfDNA levels in serum appear significantly
greater than in plasma due to contamination
from genomic DNA.
Storage conditions of blood
and time to processing
Store EDTA blood at either room
temperature or 4 C and process within 6
hours. Specialist tubes should adhere to
manufacturers’ guidelines.
Storage of blood at room temperature does
not influence cfDNA yield relative to storage
at room temperature. cfDNA levels increase
in EDTA blood processed after 6 hours.
Centrifugation speed and
time of blood
Spin blood and then re-spin plasma prior to
storage for cfDNA isolation (double spin).
Centrifugation speed and temperature (room
temperature or 4 C) is not critical.
Plasma can be contaminated with cells from
the buffy layer. The second spin helps to
minimize the potential for contamination of
plasma with cells from the buffy layer.
Method of cfDNA
isolation and quantification
Follow manufacturers recommendation for
cfDNA isolation.
Quantify by qPCR or fluorometry.
Quantification of cfDNA shows good
agreement by qPCR, dPCR and
fluorometry.*
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ples from healthy subjects and/or patients with cancer. All 10 studies (Table 3) re-
ported a significant increase in cfDNA levels in serum relative to plasma, likely
due to lysis of white blood cells in serum during clotting. In support of this, one
study also compared DNA integrity, which was higher in serum than plasma, con-
firming likely release of DNA from white blood cells (Chan et al., 2005). Accord-
ingly, use of plasma is preferable for applications where detection of tumor-
specific alterations may be masked by extraneous wild-type DNA, and the limit of
detection of a specific variant may be compromised.
Immediate processing of blood by centrifugation may not always be possible in the
clinical setting; for example, a centrifuge may not be available on-site or blood sam-
ples may be taken over a period of time during a clinic. Consistent with the notion of
DNA contamination in serum, the included studies reported a general increase in
cfDNA levels over time in unprocessed serum and EDTA blood, albeit at a slower
rate. There was significant heterogeneity in study design, with studies measuring
cfDNA levels at intervals of several hours to several days, and with some studies
omitting a baseline time point (i.e. immediate processing).
In this review, the term ‘stability’ is used to refer to the longest time point post-
venepuncture in which cfDNA levels did not significantly change relative to at base-
line (i.e. the first time point in each study). Nineteen studies investigated the effect of a
delay in blood processing on yield of cfDNA from plasma. Nine studies used ETDA
tubes only, 8 studies compared EDTA tubes with one or more specialized cfDNA
preservation tubes (Cell-Free DNA BCT, CellSave and PAXgene Blood DNA
Tube) and 1 study compared two specialized tubes. All studies using EDTA tubes re-
ported stability of cfDNA for at least 6 hours, and up to 24 hours in several studieson.2018.e00699
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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van Ginkel et al., 2017). Several studies (Denis et al., 2015; Rothwell et al., 2016;
Sherwood et al., 2016; Toro et al., 2015; van Dessel et al., 2017) did not process blood
immediately, instead using 1, 2 or 4 hours as the first time point. However, based on
data from the 10 studies that processed blood immediately, it was unlikely that cfDNA
levels increased in blood over 1, 2 and 4 hours post-venepuncture. Hence, up to 4 hour
time points were considered a suitable baseline. Four studies stored paired blood sam-
ples at room temperature and 4 C, but did not observe any significant influence of
temperature on cfDNA yield. Based on the minimum period of cfDNA stability re-
ported across these studies, it is preferable that EDTA blood is processed ideally
within 6 hours of venepuncture and stored either at room temperature or 4 C during
this time. While the Cell-Free DNA BCT is reported to stabilize blood for up to 14
days post-venepuncture, only one study in this review included time points that
extended to 14 days; and blood was reported to be stable for up to 7 days, but not
14 days. Another study reported stability for up to 10 days and the other studies
that assessed the Cell-Free DNA BCT reported stability up to the last time point
(ranging from 24 hours to 7 days). Seven days is therefore a sensible maximum
time to processing for samples from Cell-Free DNA BCT tubes.
Protocols for isolation of plasma from whole blood must ensure the resultant plasma
is completely acellular to prevent contamination with genomic DNA. This review
included 6 studies that compared the effect of centrifugation speed (range,
400e16,000g) and the number of centrifugation steps (1e4) on cfDNA yield
from plasma. The use of a second centrifugation step is common practice due to
possible disturbance of cells in the buffy layer on removal of plasma. This is sup-
ported by one study that used a second centrifugation step of 16,000g after a lower
800g first step that reported a significant decrease in cfDNA yield relative to the sin-
gle step alone (P¼ 0.01) (Swinkels et al., 2003). A double-centrifugation protocol is
desirable to minimize the potential for contamination of plasma with cells in the
buffy layer such that carry over of cells from the first centrifugation will be pelleted
in the second centrifugation. However, centrifugation speed and temperature are not
critical as these did not influence cfDNA recovery.
Methods of cfDNA isolation vary with different commercially available kits. All
require adherence to the protocol to minimize variability in recovery of cfDNA.
There are also a number of validated automated platforms available, which minimise
hands-on time and should aid in standardization, although none were tested in the
studies evaluated in this review. Among the methods analyzed in these studies,
the Qiagen QIAamp CNA Kit and DNA Blood Mini Kit were the most widely
used methods. Quantification of cfDNA was predominantly carried out by either
qPCR or fluorometry, which showed good agreement. Where qPCR is not available,
fluorometry is a quick and cost-effective method of cfDNA quantification, within the
limits of the particular assay. An advantage of PCR-based quantification is that it canon.2018.e00699
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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digital PCR (dPCR).
Based on this systematic review, we have summarized evidence-based methodological
recommendations to promote best practice in processing and analysis of cfDNA (Table
8). This review is therefore an important step in enabling research groups to increase
comparability between cfDNA analyses, helping to facilitate translation of cfDNA
intomulti-center clinical trials as a step towards implementation in the clinic. To ensure
rapiddisseminationof the results and to reach ananalytical consensus in thefield, theuse
of uniform units should also be considered for adoption by the scientific community.Declarations
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